Eli Lilly 2004 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2004 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

PIPELINE
6
A Pipeline of Innovation at Lilly
Major Marketed Products (Dates indicate the year of fi rst global launch.)
2004 Cymbalta® for major depressive disorder
for diabetic peripheral neuropathic pain (2004)
(copromoted with Quintiles Transnational Corp. in the U.S., and with
Boehringer Ingelheim elsewhere in the world, except Japan)
Alimta® for malignant pleural mesothelioma
for second-line treatment of non-small-cell lung cancer (2004)
Symbyax™ for bipolar depression
Yentreve™ for stress urinary incontinence (not approved in the U.S.)
(copromoted with Boehringer Ingelheim in major markets, except Japan)
2003 Cialis® for erectile dysfunction
(developed in a joint venture with ICOS Corp.; copromoted by Lilly ICOS
in North America and Europe and by Lilly elsewhere)
Strattera® for attention-defi cit hyperactivity disorder in children, adolescents, and adults
2002 Forteo® for treatment of men and postmenopausal women with osteoporosis
who are at high risk for a fracture
2001 Xigris® for adult severe sepsis patients at high risk of death
1999 Actos® for type 2 diabetes
(copromoted with Takeda Chemical Industries, Ltd.)
1998 Evista® for prevention of osteoporosis in postmenopausal women
for treatment of osteoporosis in postmenopausal women (1999)
1996 Zyprexa® for schizophrenia
for acute bipolar mania (2000)
Zyprexa® Zydis® tablet (2000)
for schizophrenia maintenance (2001)
as combination therapy with lithium or valproate for acute bipolar mania (2002)
for bipolar maintenance (2003)
Rapid-acting IntraMuscular formulation (2004)
Zyprexa® granules (2004; launched in Japan only)
Humalog® for treatment of type 1 and type 2 diabetes
Humalog® mixtures (1999)
1995 Gemzar® for non-small-cell lung cancer
for pancreatic cancer (1996)
for bladder cancer (2000; not approved in the U.S.)
for metastatic breast cancer (2003)
for recurrent ovarian cancer (2004; not approved in the U.S.)
ReoPro® for prevention of cardiac ischemic complications in patients undergoing
coronary intervention, such as angioplasty
for unstable angina associated with stent procedure (1997)
(developed by Centocor and marketed by Lilly, except in Japan)